Companies such as Pfizer Inc. (U.S.), Johnson & Johnson Services, Inc. (U.S.), Sanofi (France), Swedish Orphan Biovitrum AB (publ) (Sweden) and Bellicum Pharmaceuticals, Inc. (U.S.) are major players in haemophagocytic lymphohistiocytosis treatment market.
In January 2025, Teva announced the launch of Copaxone (glatiramer acetate injection) for the treatment of secondary HLH in patients with multiple sclerosis. This launch represents Teva's expansion into the HLH treatment market, offering a new therapeutic option for patients with this rare condition
The countries covered in the Haemophagocytic Lymphohistiocytosis Treatment market are U.S., Canada, Mexico, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, U.A.E., South Africa, Egypt, Israel, and rest of Middle East and Africa.
Corporate Email ID Only (Avoid Using Generic mail ID such as Gmail)
Consent Preferences
We use cookies to improve your experience We use cookies to deliver the best possible experience on our website. To learn more, visit our Privacy Policy. By continuing to use this site, or closing this box, you consent to our use of cookies. Cookie Notice.